Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million Feb 15, 2023 02:00AM
Bavarian Nordic Announces the Sale of Priority Review Voucher Dec 17, 2019 01:36PM
Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak Dec 9, 2019 01:00AM
Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine Nov 14, 2019 02:23AM
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox Vaccine Nov 11, 2019 01:30AM


Nov 7, 2019 06:03AM Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen
Nov 6, 2019 05:33AM Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature Communications
Oct 31, 2019 08:24AM Investigational Ebola Vaccine from Janssen and Bavarian Nordic to Support Outbreak Response in Democratic Republic of the Congo
Oct 21, 2019 02:59AM Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline
Oct 8, 2019 02:44AM Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine
Oct 3, 2019 02:09AM Bavarian Nordic Completes Enrollment of Phase 2 Trial in Chordoma Patients
Sep 24, 2019 01:45PM Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults
Jun 25, 2019 02:46AM Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense Programs
Jun 5, 2019 03:11PM Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
Mar 21, 2019 05:09AM Bavarian Nordic Announces Annual Report 2018
Feb 21, 2019 01:34PM Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
Jan 25, 2019 05:59AM Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
Jan 24, 2019 01:31AM Bavarian Nordic Advances Development of Equine Encephalitis Virus Vaccine
Jan 18, 2019 01:16AM Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine
Dec 21, 2018 03:29PM Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine
Nov 2, 2018 09:56AM Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers
Nov 1, 2018 09:34AM Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma
Sep 18, 2018 02:45PM Bavarian Nordic (BVNRY) Reports Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer
Sep 18, 2018 01:51PM Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer
Aug 8, 2018 08:08AM Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
Jul 11, 2018 06:02AM Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
May 16, 2018 05:01PM Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 16, 2018 08:55AM Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus
Mar 8, 2018 08:59AM Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
Mar 6, 2018 08:33AM Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
Feb 26, 2018 04:40AM Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
Feb 6, 2018 12:23PM Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
Jan 19, 2018 01:01AM Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
Nov 21, 2017 01:06PM Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine
Nov 9, 2017 01:32AM Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
Sep 14, 2015 04:07PM Bavarian Nordic Receives Contract Valued at USD 9 Million from Janssen as part of Advanced Development of Prime-Boost Ebola Vaccine Regimen
Aug 18, 2015 10:09AM Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)
Jul 15, 2015 02:10AM Bavarian Nordic Announces that the Oxford Vaccines Group has Initiated a Phase 2 Study of the Ebola Prime-Boost Vaccine Regimen Combining MVA-BN(r) Filo and Janssen's AdVac(r) Technology
May 13, 2015 01:36AM Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE(r) Smallpox Vaccine
May 12, 2015 02:04PM Bavarian Nordic Announces Presentation of Preliminary Phase 1 Results for the Ebola Prime-Boost Vaccine Regimen of MVA-BN(r) Filo and Janssen's AdVac(r) technology